InVitae (NVTA) Misses Q3 EPS by 10c

InVitae (NYSE: NVTA) reported Q3 EPS of ($0.81), $0.10 worse than the analyst estimate of ($0.71). Revenue for the quarter came in at $114.4 million versus the consensus estimate of $126.55 million.

For earnings history and earnings-related data on InVitae (NVTA) click here.

You May Also Be Interested In

• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recover
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c